NBI-98854 50 mg capsule
NBI-98854-1303
Phase 1 small_molecule completed
Quick answer
NBI-98854 50 mg capsule for Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects is a Phase 1 program (small_molecule) at NEUROCRINE BIOSCIENCES INC with 1 ClinicalTrials.gov record(s).
Program details
- Company
- NEUROCRINE BIOSCIENCES INC
- Indication
- Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed